Steris (NYSE:STE) updated its FY 2019 earnings guidance on Monday. The company provided EPS guidance of $4.74-4.84 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.76. The company issued revenue guidance of $2.751-2.751 billion, compared to the consensus revenue estimate of $2.75 billion.
STE has been the subject of several research reports. KeyCorp lifted their target price on shares of Steris from $120.00 to $132.00 and gave the company an overweight rating in a report on Tuesday, November 13th. Zacks Investment Research reiterated a buy rating and issued a $132.00 target price on shares of Steris in a report on Friday, November 16th. Finally, Sidoti lifted their target price on shares of Steris from $155.00 to $157.00 and gave the company a buy rating in a report on Thursday, December 6th. Five equities research analysts have rated the stock with a buy rating, Steris presently has an average rating of Buy and a consensus target price of $134.20.
Steris stock traded up $1.27 during trading on Monday, hitting $119.86. The company had a trading volume of 772,423 shares, compared to its average volume of 413,651. Steris has a 1-year low of $83.44 and a 1-year high of $121.67. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.01 and a current ratio of 2.63. The company has a market capitalization of $10.03 billion, a PE ratio of 28.88 and a beta of 1.04.
In related news, VP John Adam Zangerle sold 3,000 shares of Steris stock in a transaction that occurred on Friday, January 25th. The shares were sold at an average price of $115.00, for a total value of $345,000.00. Following the completion of the sale, the vice president now owns 33,796 shares in the company, valued at approximately $3,886,540. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.38% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was reported by Zolmax and is owned by of Zolmax. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://zolmax.com/investing/steris-ste-issues-fy-2019-earnings-guidance/2892357.html.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Featured Article: Marijuana Stocks
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.